Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor (Q46048249)

19 December 2017

title

Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor (English)

1 reference

19 December 2017

author

Domenico D'Arca

1

1 reference

19 December 2017

Matteo Fassan

8

1 reference

19 December 2017

Carlo Maria Croce

9

object named as

Carlo M Croce

1 reference

19 December 2017

James LeNoir

2

1 reference

19 December 2017

Bernadette Wildemore

3

1 reference

19 December 2017

Fedra Gottardo

4

1 reference

19 December 2017

Emma Bragantini

5

1 reference

19 December 2017

Dolores Shupp-Byrne

6

1 reference

19 December 2017

Nicola Zanesi

7

1 reference

19 December 2017

Leonard G Gomella

10

1 reference

19 December 2017

Raffaele Baffa

11

1 reference

19 December 2017

publication date

16 April 2009

1 reference

19 December 2017

published in

Urologic Oncology

1 reference

19 December 2017

volume

28

1 reference

19 December 2017

issue

2

1 reference

19 December 2017

page(s)

189-194

1 reference

19 December 2017

Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Early trials probe COX-2 inhibitors' cancer-fighting potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Inactivation of the FHIT gene favors bladder cancer development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Loss of FHIT expression in transitional cell carcinoma of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

7 January 2021

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

FHIT gene therapy prevents tumor development in Fhit-deficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

Muir-Torre-like syndrome in Fhit-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.016

10.1016/J.UROLONC.2009.01.016

7 January 2021

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017